[Rosacea 2009 : new advances in pathophysiology, clinical staging and therapeutic strategies].
Rosacea is one of the most common dermatoses of adults. In recent years many studies have contributed to a better understanding of the pathophysiology of rosacea. They suggest that an altered innate immune response is involved in the vascular and inflammatory manifestations seen in rosacea. A good understanding of the disease and its special features is necessary for the differential diagnosis of the many clinical subtypes and for a stage- and phase-specific treatment approach. Topical treatments that are widely accepted are metronidazole and azelaic acid; agents under investigation that show promise include permethrin, calcineurin inhibitors and sulfur compounds. For systemic therapy antibiotics (tetracyclines, macrolides) and recently doxycycline in anti-inflammatory rather than anti-microbial dosages are used, as well as isotretinoin in severe cases. Findings such as rhinophyma and telangiectases can be treated using different laser systems or dermabrasion. This article gives an overview regarding rosacea, a challenging condition with multiple therapeutic options.
Sobottka
A
A
Zentrum für Dermatologie, Allergologie und Dermatochirurgie - Kompetenzzentrum Hautkrebs, HELIOS-Klinikum Wuppertal, Heusner Str. 40, 42283, Wuppertal, Deutschland. axel.sobottka@helios-kliniken.de
Lehmann
P
P
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D023181:Antimicrobial Cationic Peptides / Q000378:metabolism; D003879:Dermatologic Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D008297:Male; D051379:Mice; D009536:Niacinamide / Q000378:metabolism; D012224:Rhinophyma / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D012307:Risk Factors; D012393:Rosacea / Q000175:diagnosis / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D012867:Skin / Q000503:physiopathology; D013684:Telangiectasis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D014466:Ultraviolet Rays / Q000009:adverse effects; D054804:Cathelicidins
D000900:Anti-Bacterial Agents; D023181:Antimicrobial Cationic Peptides; D003879:Dermatologic Agents; D009536:Niacinamide; D015474:Isotretinoin; D054804:Cathelicidins